ArticleCancers2021
A Novel Orthotopic Liver Cancer Model for Creating a Human-like Tumor Microenvironment.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Stroma-oriented tumor microenvironment facilitates intraosseous ameloblastoma tumor growth.iScience · 2026Article
- Pan-cancer landscape of protein kinase D3: An integrative TCGA multi-omics analysis of clinical, molecular, and immunological roles.PloS one · 2026Article
- Review
- Primary liver cancer organoids and their application to research and therapy.Journal of the National Cancer Center · 2024Review
- Organoid as a promising tool for primary liver cancer research: a comprehensive review.Cell & bioscience · 2024Review
- Orthotopic and metastatic tumour models in preclinical cancer research.Pharmacology & therapeutics · 2024Review
- Construction of tumor organoids and their application to cancer research and therapy.Theranostics · 2024Review
- Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors.Stem cell reviews and reports · 2023Review
- Combined Administration of Escitalopram Oxalate and Nivolumab Exhibits Synergistic Growth-Inhibitory Effects on Liver Cancer Cells through Inducing Apoptosis.International journal of molecular sciences · 2023Article
- Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer.Frontiers in immunology · 2023Review
- Advances in Tumor Organoids for the Evaluation of Drugs: A Bibliographic Review.Pharmaceutics · 2022Review
- Tumor organoids: applications in cancer modeling and potentials in precision medicine.Journal of hematology & oncology · 2022Review
- Review
- The Importance of the Tumor Microenvironment to Understand Tumor Origin, Evolution, and Treatment Response.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. This study aims to develop a new method to generate an HCC mouse model with a human tumor, and imitates the tumor microenvironment (TME) of clinical patients. Here, we have generated functional, three-dimensional sheet-like human HCC organoids in vitro, using luciferase-expressing Huh7 cells, human iPSC-derived endothelial cells (iPSC-EC), and human iPSC-derived mesenchymal cells (iPSC-MC). The HCC organoid, capped by ultra-purified alginate gel, was implanted into the disrupted liver using an ultrasonic homogenizer in the immune-deficient mouse, which improved the survival and engraftment rate. We successfully introduced different types of controllable TME into the model and studied the roles of TME in HCC tumor growth. The results showed the role of the iPSC-EC and iPSC-MC combination, especially the iPSC-MC, in promoting HCC growth. We also demonstrated that liver fibrosis could promote HCC tumor growth. However, it is not affected by non-alcoholic fatty liver disease. Furthermore, the implantation of HCC organoids to humanized mice demonstrated that the immune response is important in slowing down tumor growth at an early stage. In conclusion, we have created an HCC model that is useful for studying HCC development and developing new treatment options in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.